Intuitive Surgical stock: Baird raises target for Intuitive Surgical stock to USD 550

Published on 10/23/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Baird lifts its target from USD 513.00 to USD 550.00 on October 21, 2026. Intuitive Surgical stock costs EUR 403.95 on October 23, 2026.

Baird target raised

Robert W. Baird raised its Intuitive Surgical target from USD 513.00 to USD 550.00 on October 21, 2026.
Third-quarter 2026 revenue reached USD 3.05 billion, up 22.00 percent year over year.
Intuitive Surgical stock was at EUR 403.95 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST.
Intuitive Surgical placed 546 da Vinci systems in the third quarter of 2026.

Fotorealistischer Operationssaal mit einem generischen Roboterchirurgiesystem mit vier Instrumentenarmen über einem blau drapierten Patienten, helles OP-Licht, unscharfe Chirurgensilhouetten im Hintergrund — Intuitive Surgical US46120E6023 zeigt fotorealistischen generischen OP-Roboter mit vier Armen im sterilen Operationssaal, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) drew a higher valuation target from Robert W. Baird, which raised its target from USD 513.00 to USD 550.00 on October 21, 2026, while keeping an Outperform rating. MarketBeat reported the change. The stock was at EUR 403.95 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST.

Revenue growth stays broad

Intuitive reported third-quarter 2026 revenue of USD 3.05 billion, an increase of 22.00 percent from USD 2.51 billion in the third quarter of 2025. The company also reported non-GAAP net income of USD 1.05 billion, or USD 3.00 in non-GAAP diluted earnings per share, versus USD 867.00 million and USD 2.40 in the year-earlier quarter. These figures came from the company's October 20, 2026 earnings release, published on its investor site.

Procedure growth supported the result. Worldwide da Vinci and Ion procedures increased 15.00 percent year over year in the third quarter of 2026, while da Vinci procedures rose 14.00 percent and Ion procedures increased 31.00 percent. Intuitive placed 546 da Vinci systems, compared with 427 in the third quarter of 2025, and 56 Ion systems, compared with 50.

What supports the higher target?

The installed base provides another measurable operating indicator. Intuitive had 12,094 da Vinci systems installed on September 30, 2026, up 12.00 percent from 10,763 one year earlier. Its Ion installed base reached 1,152 systems, an increase of 21.00 percent from 954.

The earnings release also reported a USD 450.00 million pre-tax litigation charge in the third quarter of 2026. GAAP net income attributable to Intuitive Surgical was USD 522.80 million, or USD 1.49 per diluted share, compared with USD 704.40 million and USD 1.95 in the third quarter of 2025. Intuitive Surgical said the charge related to a proposed antitrust litigation settlement.

Next dates and valuation

Intuitive Surgical held its third-quarter 2026 earnings conference call on October 20, 2026. Its investor-relations calendar also lists the next scheduled conference appearance as the Wells Fargo Healthcare Conference on September 9, 2026, a date that has passed.

The combination of 22.00 percent revenue growth and 15.00 percent procedure growth gives the latest quarterly figures a clear operating contrast. The litigation charge reduced GAAP earnings, while the company's non-GAAP figures showed higher operating performance after adjustments.

Stock price in euros

Intuitive Surgical was trading at EUR 403.95 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST. The latest reported operating figures and Baird's USD 550.00 target give investors two separate measures for assessing the stock's valuation and execution.

The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.